Sign Up And Receive Our Latest Promotions!
.svg){kind=small}
Disease apps for clinics
Despite advances in retinal imaging technology, patient disease activity can be missed in vision-threatening conditions. This oversight in everyday practice has the potential for undertreatment in patients. In addition, treatment delays further impact vision, worsening outcomes. Delays are in part due to a lack of awareness and urgency from the patient.
RetinAI’s Disease Evaluation Apps are accessed via Heidelberg AppWay. AppWay is a secure data transfer portal integrated in Heidelberg’s HEYEX 2. The Disease Apps provide expert-level analysis of a patient’s OCT volumes. Results are generated during the patient’s visit to complement evaluation and management of retinal diseases. The results can be used to better understand disease and status of biomarkers, and can provide valuable education and visualization of disease and biomarkers, empowering patients to be engaged in their disease management.
RetinAI’s Disease Evaluation Apps powered by Certified* AI Models:
These models were developed from real world evidence across multiple retinal diseases comparing the models’ performance to that of expert graders, resulting in similar performance achieved.
These models were designed to provide valuable insights for patient management.
FLUID SEGMENTATION MODEL
Identifies and quantifies the volume of pathological fluid such as intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelium detachment (PED).
LAYER SEGMENTATION MODEL
MEASURES TOTAL RETINAL AND LAYER THICKNESS FOR THE FOLLOWING LAYERS:
Retinal Nerve Fiber Layer (RNFL; Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL); Inner Nuclear Layer (INL) + Outer Plexiform Layer (OPL); Outer Nuclear Layer (ONL); Photoreceptor (PR) + Retinal Pigment Epithelium (RPE; and Choriocapillaris (CC) + Choroidal Stroma (CS).
MACULA BIOMARKERS MODEL
PROVIDES PROBABILITY OF PRESENCE/ABSENCE OF RETINAL BIOMARKERS AT A B-SCAN LEVEL IN OCT VOLUMES. THE BIOMARKERS IDENTIFIED ARE:
Fluids (SRF, IRF and Fibrous PED), Hyper reflective Foci (HF), Drusen, Reticular Pseudodrusen (RPD), Epiretinal Membrane (EPM), Geographic Atrophy (GA) and Outer Retinal Atrophy (ORA).
Geographic Atrophy (GA) model
PROVIDES SEGMENTATION OF GA FROM OCT SCANS AND SIMULATION OF ATROPHY PROGRESSION BASED ON VISIT DATA. RESEARCH USE ONLY APPS FOR GEAOGRAPHIC ATROPHY.
GA segmentation on Bscan, en-face GA segmentation in Localiser image, en-face laver information for PR+RR and CS+CC, affected GA area calculation, progression prediction
RetinAI’s Disease Evaluation Apps on Heidelberg AppWay
As a result, to comprehensively understand a patient’s disease, it’s important to monitor relevant endpoints and biomarkers to obtain a full picture of the patient’s imaging data. RetinAI’s Disease Evaluation Apps provide the ability to quickly quantify relevant biomarkers to monitor changes across commonly managed diseases in Retina.
Discover our Apps on Heidelberg AppWay, pricing based on usage level
With a subscription, you get access to all available RetinAI apps (nAMD, dAMD, DR/DME, CME, GA).
Get your credits now and only pay per report when you use the apps, no monthly base fee applies.
If you are interested in batch data analysis using AI, read more about our RetinAI Discovery CORE®
VIA Heidelberg appway
Want to use RetinAI's Apps on other devices?
*Disclaimer
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.
